Analysis of Selected Biochemical Parameters in Cerebrospinal Fluid and Peripheral Blood in the Treatment of Neuropathic Pain Using Spinal Cord Stimulation (SCS)

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-80
SponsorPawel Sokal

About this trial

This project aims to identify key cells and molecules involved in the development and modulation of neuropathic pain treated with spinal cord stimulation (SCS). By measuring concentrations of selected inflammatory mediators and signaling molecules (e.g., IL-1β, IL-6, IL-17, IL-33, BDNF, VEGF, GABA) in the blood and cerebrospinal fluid (CSF) of patients undergoing SCS, the study seeks to better understand the mechanism of action of SCS. The findings may allow the development of predictive biomarkers, help tailor stimulation parameters, and support complementary pharmacotherapy. The project also explores differences in response to various stimulation types and the role of glial cells in SCS efficacy, with a view to improving patient outcomes through more personalized neuromodulation strategies.

Eligibility criteria

Qualifiers

Age 18-80

PSPS or CRPS

Neuropathic pain for at least 6 months

Disqualifiers

Drug/alcohol addiction

Malignant tumour

Psychiatric disorders

Active infection

Trial design

Treatments tested in this trial

  • Immunological Factors

Treatment groups

30 Participants
are divided into 1 treatment group

Sponsors and collaborators

Pawel Sokal

Lead sponsor

Jan Biziel University Hospital No 2 in Bydgoszcz

Sponsor institution

Department of Neurosurgery Collegium Medicum Nicolaus Copernicus University

Collaborator

Nicolaus Copernicus University in Toruń, Collegium Medicum in Bydgoszcz

Collaborator